Zelboraf
6 Topics Found
Vemurafenib
Vemurafenib (INN, marketed as Zelboraf) is an inhibitor of the B-Raf enzyme developed by Plexxikon (now part of Daiichi-Sankyo) and Genentech for the treatment of late-stage melanoma.[1] The name "vemurafenib" comes from V600E mutated BRAF inhibition. Contents 1 Approvals 2 Mechanism of action 2.1 Resistance 3 Clinical trials 3.1 Side effects 4 References 5 Further reading 6 External links Approvals Vemurafenib received FDA approval for the treatment of late-stage...
I've been taking Zelboraf for about 2 weeks and have severe joint pain. I'm looking for a way to combat the joint pain as am very active and still work. ## Have you consulted your doctor? Zelboraf contains the active ingredient Vemurafenib and is used to treat late stage Melanoma. In light of your medical condition and being on such a medication for it, only a doctor will be able to properly advise of what you can try for the side effects.
1 REPLY
Filed under
Zelboraf
Drug Index
Vemurafenib (INN, marketed as Zelboraf) is an inhibitor of the B-Raf enzyme developed by Plexxikon (now part of Daiichi-Sankyo) and Genentech for the treatment of late-stage melanoma.[1] The name "vemurafenib" comes from V600E mutated BRAF inhibition. Contents 1 Approvals 2 Mechanism of action 2.1 Resistance 3 Clinical trials 3.1 Side effects 4 References 5 Further reading 6 External links Approvals Vemurafenib received FDA approval for the treatment of late-stage...
Cobimetinib
Cobimetinib, sold under the brand name Cotellic, is an anti-cancer medication used in combination with vemurafenib (Zelboraf) alone or with both vemurafenib and atezolizumab (Tecentriq) to treat melanoma.[1][5] Cobimetinib is a MEK inhibitor.[1] Cotellic, Zelboraf, and Tecentriq are all marketed by Genentech, a subsidiary of Roche.[1][5][6] The most common side effects include diarrhea, rash, nause...
Drug Index
Cobimetinib, sold under the brand name Cotellic, is an anti-cancer medication used in combination with vemurafenib (Zelboraf) alone or with both vemurafenib and atezolizumab (Tecentriq) to treat melanoma.[1][5] Cobimetinib is a MEK inhibitor.[1] Cotellic, Zelboraf, and Tecentriq are all marketed by Genentech, a subsidiary of Roche.[1][5][6] The most common side effects include diarrhea, rash, nause...
NDC Database
Zelboraf 240 mg Oral Tablet by Genentech, Inc. ## Markings: VEM ## Shape: Oval ## Package Codes: 50242-090-01, 50242-090-02, 50242-090-86 ## Active Ingredients: Vemurafenib